StreetInsider.com News Articles

Form 4 Q32 Bio Inc. For: Oct 06 Filed by: Violette Shelia M.

Wed, 14 Oct 2026 17:30:00 -0400

si-local-file:///var/storage/secattach/20261014/27188004.html

Form 4 Q32 Bio Inc. For: Oct 06 Filed by: Morrison Jodie Pope

Wed, 14 Oct 2026 17:30:00 -0400

si-local-file:///var/storage/secattach/20261014/27188003.html

Form 4 Q32 Bio Inc. For: Oct 06 Filed by: Kalowski Lee

Wed, 14 Oct 2026 17:30:00 -0400

si-local-file:///var/storage/secattach/20261014/27187998.html

Leerink Starts Q32 Bio Inc. (QTTB) at Outperform

Mon, 12 Oct 2026 06:17:16 -0400

Leerink analyst Willi Soghikian initiates coverage on Q32 Bio Inc. (NASDAQ: QTTB) with a Outperform rating and a price target of $40.00.

For an analyst ratings summary and ratings history on Q32 Bio Inc. click here. For more ratings news on Q32 Bio Inc. click here.

Shares of Q32 Bio Inc. closed at $8.34 yesterday.

Form SCHEDULE 13G Q32 Bio Inc. Filed by: Frazier Life Sciences Public Fund, L.P.

Fri, 09 Oct 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20261009/27171875.html

Why this analyst says selloff in this stock "is a misunderstanding"

Mon, 05 Oct 2026 20:00:00 -0400

Oppenheimer reiterated an Outperform rating on a clinical-stage biotech after its shares fell sharply last week following a detailed data presentation, saying the drop offers an attractive entry point.

Analyst Jay Olson kept a $40 price target on Q32 Bio (NASDAQ: QTTB), which presented detailed Part B data from its SIGNAL-AA trial of bempikibart in alopecia areata, building on positive topline results reported in July.

But despite the promising data, QTTB plunged 13.2% on Wednesday. Olson said he was "surprised by the weakness," which he thinks may reflect a perception of lower efficacy in prior JAK non-responders, along with profit-taking after the

Why this analyst says selloff in this stock "is a misunderstanding"

Mon, 05 Oct 2026 20:00:00 -0400

Oppenheimer on Q32 Bio Inc. (QTTB): ' We view the weakness as a misunderstanding'

Thu, 01 Oct 2026 06:03:54 -0400

Oppenheimer analyst Jay Olson reiterated an Outperform rating and $40.00 price target on Q32 Bio Inc. (NASDAQ: QTTB).

The analyst comments "QTTB presented detailed SIGNAL-AA Part-B data for bempikibart (bempi) in alopecia areata (AA), building upon positive topline results reported in July. While headline efficacy was known, we are encouraged by incremental data demonstrating durable and in some patients, deepening response during the 16-week off-drug follow-up period, which further differentiate bempi's profile from JAKs. Despite the promising data, QTTB shares were down 13.2% vs. NBI: +0.5% on 09/30. We were surprised by the weakness, possibly driven by a perception of lower

Form 8-K Q32 Bio Inc. For: Sep 30

Wed, 30 Sep 2026 09:20:00 -0400

si-local-file:///var/storage/secattach/20260930/27126499.html

Q32 Bio presents Phase 2a alopecia areata trial data at EADV 2026

Wed, 30 Sep 2026 09:17:18 -0400

Q32 Bio Inc. (Nasdaq: QTTB) presented results from Part B of its SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with severe or very severe alopecia areata at the European Academy of Dermatology and Venereology Congress 2026 on Sept. 30.

The open-label trial enrolled 33 patients with baseline Severity of Alopecia Tool (SALT) scores of 50–100 and a maximum current episode duration of four years. Of those enrolled, 36.4% had prior exposure to oral JAK inhibitors. Patients received bempikibart 200mg weekly for four loading doses, followed by 200mg every other week for 32 weeks, then a 16-week off-drug follow-up period.

Q32 Bio presents Phase 2a alopecia areata trial data at EADV 2026

Wed, 30 Sep 2026 09:17:18 -0400

Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026

Wed, 30 Sep 2026 09:15:00 -0400

-- Clinically meaningful efficacy data observed on primary and key secondary endpoints at Week 36 --

-- Robust durability, including maintenance and deepening of response, observed following the 16-week off-drug period supporting potential for less frequent, chronic maintenance dosing --

-- Mechanism of action supported by biomarker results and

Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026

Wed, 30 Sep 2026 09:15:00 -0400

-- Clinically meaningful efficacy data observed on primary and key secondary endpoints at Week 36 --

-- Robust durability, including maintenance and deepening of response, observed following the 16-week off-drug period supporting potential for less frequent, chronic maintenance dosing --

-- Mechanism of action supported by biomarker results and

Clear Street Starts Q32 Bio Inc. (QTTB) at Buy

Mon, 28 Sep 2026 16:35:22 -0400
(Updated - September 28, 2026 4:35 PM EDT)
Clear Street analyst Kaver initiates coverage on Q32 Bio Inc. (NASDAQ: QTTB) with a Buy rating and a price target of $38.00.
The analyst comments "We initiate coverage of QTTB with a Buy rating and a $38 PT, driven by strong conviction in bempikibart’s path to a competitive severe-AA label, with P3 initiation expected in 1H27. Bempikibart has demonstrated JAKi-like efficacy (the only approved class in severe AA) alongside an unparalleled safety profile, without JAKi-class serious safety concerns or regular lab monitoring—supporting potential preferred 1L positioning. Its comprehensive MOA, aimed at restoring immune homeostasis

Clear Street Starts Q32 Bio Inc. (QTTB) at Buy

Mon, 28 Sep 2026 16:35:22 -0400
(Updated - September 28, 2026 4:35 PM EDT)
Clear Street analyst Kaver initiates coverage on Q32 Bio Inc. (NASDAQ: QTTB) with a Buy rating and a price target of $38.00.
The analyst comments "We initiate coverage of QTTB with a Buy rating and a $38 PT, driven by strong conviction in bempikibart’s path to a competitive severe-AA label, with P3 initiation expected in 1H27. Bempikibart has demonstrated JAKi-like efficacy (the only approved class in severe AA) alongside an unparalleled safety profile, without JAKi-class serious safety concerns or regular lab monitoring—supporting potential preferred 1L positioning. Its comprehensive MOA, aimed at restoring immune homeostasis

Jefferies Starts Q32 Bio Inc. (QTTB) at Buy

Mon, 28 Sep 2026 06:12:39 -0400

Jefferies analyst Maury Raycroft initiates coverage on Q32 Bio Inc. (NASDAQ: QTTB) with a Buy rating and a price target of $29.00.
The analyst comments "QTTB plans to start an alopecia areata ph.III 1H27 w/ anti-IL7Rα bempikibart, which showed favorable ph.II hair regrowth data vs competitors. We see a disconnect w/ the (-)ve EV stock, given alopecia's pot'l (est $1.2B peak rev) & events ahead: 1) 16-wk off-tx data 9/30 @EADV; 2) NKTR 24-wk off-tx data 4Q pot'ly 10/1 @EADV; 3) ARGX ph.I data 2H; 4) ph.III reg update late'26/early'27; 5) expansion plans ~1H27; 6) OLE data 2H27. Initiate@Buy; $29 PT"
For

Jefferies Starts Q32 Bio Inc. (QTTB) at Buy

Mon, 28 Sep 2026 06:12:39 -0400

Jefferies analyst Maury Raycroft initiates coverage on Q32 Bio Inc. (NASDAQ: QTTB) with a Buy rating and a price target of $29.00.
The analyst comments "QTTB plans to start an alopecia areata ph.III 1H27 w/ anti-IL7Rα bempikibart, which showed favorable ph.II hair regrowth data vs competitors. We see a disconnect w/ the (-)ve EV stock, given alopecia's pot'l (est $1.2B peak rev) & events ahead: 1) 16-wk off-tx data 9/30 @EADV; 2) NKTR 24-wk off-tx data 4Q pot'ly 10/1 @EADV; 3) ARGX ph.I data 2H; 4) ph.III reg update late'26/early'27; 5) expansion plans ~1H27; 6) OLE data 2H27. Initiate@Buy; $29 PT"
For

Q32 Bio to present bempikibart trial data at EADV congress

Mon, 21 Sep 2026 09:16:26 -0400

Q32 Bio Inc. (Nasdaq: QTTB) announced it will present results from Part B of its SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with severe or very severe alopecia areata at the European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria, running September 30 through October 3, 2026.
The presentations will include additional 36-week results and initial findings from a 16-week off-drug period from the trial. Bempikibart is a fully human anti-IL-7Rα antibody designed to block IL-7 and TSLP signaling.
An oral presentation titled "Bempikibart, a novel IL-7Rα antibody, produces hair regrowth that persists off treatment in severe and

Q32 Bio Announces Upcoming Late-Breaking Presentation of Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata at the European Academy of Dermatology and Venereology Co

Mon, 21 Sep 2026 09:15:00 -0400

-- Late-breaking oral and poster presentations to feature additional 36-week results and initial findings from the 16-week off-drug period from Part B of the SIGNAL-AA clinical trial of bempikibart in alopecia areata --

WALTHAM, Mass., Sept. 21, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical-stage biotechnology company focused on developing innovative therapies

Q32 Bio Announces Upcoming Late-Breaking Presentation of Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata at the European Academy of Dermatology and Venereology Co

Mon, 21 Sep 2026 09:15:00 -0400

-- Late-breaking oral and poster presentations to feature additional 36-week results and initial findings from the 16-week off-drug period from Part B of the SIGNAL-AA clinical trial of bempikibart in alopecia areata --

WALTHAM, Mass., Sept. 21, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical-stage biotechnology company focused on developing innovative therapies

Q32 Bio (QTTB) Reiterated at Overweight by Cantor Fitzgerald

Wed, 16 Sep 2026 07:34:11 -0400

Cantor Fitzgerald analyst Imogen Mansfield reiterated an Overweight rating n Q32 Bio Inc. (NASDAQ: QTTB).
The analyst commented, "JAKs are not disease-modifying because hair loss resumes on discontinuation. Updated data at EADV for QTTB's (OW) bempikibart in AA (following 4mos off therapy) could demonstrate durable disease control and potential disease modification,"
For an analyst ratings summary and ratings history on Q32 Bio Inc. click here. For more ratings news on Q32 Bio Inc. click here.
Shares of Q32 Bio Inc. closed at $11.17 yesterday.

Form 8-K Q32 Bio Inc. For: Sep 14

Mon, 14 Sep 2026 07:16:00 -0400
si-local-file:///var/storage/secattach/20260914/27055316.html

Q32 Bio names new chief medical and chief development officers

Mon, 14 Sep 2026 06:59:16 -0400

Q32 Bio Inc. (Nasdaq: QTTB), a clinical-stage biotechnology company focused on alopecia areata and other autoimmune and inflammatory diseases, has appointed José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer, according to a press release.

Dr. Trevejo previously served as Chief Medical Officer and Head of Clinical Pipeline Strategy at Enveda Therapeutics. Before that, he was Chief Medical Officer at Tarsus Pharmaceuticals, where he helped lead the FDA approval of XDEMVY, a treatment for Demodex blepharitis. He also held roles at Rocket Pharmaceuticals, Genentech, and Vertex Pharmaceuticals. He earned his M.D. and Ph.D. from

Q32 Bio Appoints José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer

Mon, 14 Sep 2026 06:59:00 -0400

-- Dr. Trevejo is a physician-scientist and biotechnology executive with over 20 years of experience spanning dermatology and late-stage clinical development --

-- Dr. Hershberger is a drug development leader with over 30 years of experience spanning late-stage development operations and regulatory strategy --

WALTHAM, Mass.,

Q32 Bio Appoints José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer

Mon, 14 Sep 2026 06:59:00 -0400

-- Dr. Trevejo is a physician-scientist and biotechnology executive with over 20 years of experience spanning dermatology and late-stage clinical development --

-- Dr. Hershberger is a drug development leader with over 30 years of experience spanning late-stage development operations and regulatory strategy --

WALTHAM, Mass.,

StreetInsider.com News Articles

Form 4 Q32 Bio Inc. For: Oct 06 Filed by: Violette Shelia M.

Form 4 Q32 Bio Inc. For: Oct 06 Filed by: Morrison Jodie Pope

Form 4 Q32 Bio Inc. For: Oct 06 Filed by: Kalowski Lee

Leerink Starts Q32 Bio Inc. (QTTB) at Outperform

Form SCHEDULE 13G Q32 Bio Inc. Filed by: Frazier Life Sciences Public Fund, L.P.

​Why this analyst says selloff in this stock "is a misunderstanding"

​Why this analyst says selloff in this stock "is a misunderstanding"

Oppenheimer on Q32 Bio Inc. (QTTB): ' We view the weakness as a misunderstanding'

Form 8-K Q32 Bio Inc. For: Sep 30

Q32 Bio presents Phase 2a alopecia areata trial data at EADV 2026

Q32 Bio presents Phase 2a alopecia areata trial data at EADV 2026

Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026

Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026

Clear Street Starts Q32 Bio Inc. (QTTB) at Buy

Clear Street Starts Q32 Bio Inc. (QTTB) at Buy

Jefferies Starts Q32 Bio Inc. (QTTB) at Buy

Jefferies Starts Q32 Bio Inc. (QTTB) at Buy

Q32 Bio to present bempikibart trial data at EADV congress

Q32 Bio Announces Upcoming Late-Breaking Presentation of Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata at the European Academy of Dermatology and Venereology Co

Q32 Bio Announces Upcoming Late-Breaking Presentation of Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata at the European Academy of Dermatology and Venereology Co

Q32 Bio (QTTB) Reiterated at Overweight by Cantor Fitzgerald

Form 8-K Q32 Bio Inc. For: Sep 14

Q32 Bio names new chief medical and chief development officers

Q32 Bio Appoints José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer

Q32 Bio Appoints José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer

Why this analyst says selloff in this stock "is a misunderstanding"

Why this analyst says selloff in this stock "is a misunderstanding"